VivoSeq
Cardiovascular

Portal Vein Thrombosis

21

Pipeline Programs↗

6

Active Trials↗

10

Companies Involved↗

Portal vein thrombosis is an emerging landscape with 21 programs across 10 companies. The most active players are Octapharma, Roche, Eisai. 7 therapies are approved with 6 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

48/100

Pipeline Velocity

15/100

Mech. Concentration

18/100

Completion Rate

67/100

Attrition Rate

16/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Octapharma logo

Octapharma

1 program

Phase 1Roche logo

Roche

1 program

Phase 2Eisai logo

Eisai

1 program

Phase 2N

Nihon Pharmaceutical Co., Ltd

1 program

Phase 3Sanofi logo

Sanofi

1 program

Phase 3Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Approved

Pipeline

Programs by Phase

Analysis

Modality Breakdown

96%

Small molecule

23 of 24 classified programs — the dominant modality here.

4%ALL OTHERSMonoclonal antibody14%

Small molecule leads; the ring shows all 24 classified programs, each share of the total. Modality classified for 100% of 24 pipeline programs.

Analysis

Trial Status

25

clinical trials

Completed8 · 32%
Unknown status7 · 28%
Withdrawn4 · 16%
Recruiting3 · 12%
Not yet recruiting3 · 12%

Clinical Trials

Trial Activity

25 trials

SBRT With Immunotherapy and Atezo-Bev in HCC With Major Portal Vein Thrombosis
Recruiting·—·Phase 2·NCT06823375·40 enrolled
Efficacy of Apixaban in Treating Portal Vein Thrombosis Occurring More Than One Year After LSD
Recruiting·NNorthern Jiangsu People's Hospital·N/A·NCT07461532·40 enrolled
Efficacy of Apixaban in the Treatment of Portal Vein Thrombosis Occurring More Than One Year After LS
Recruiting·NNorthern Jiangsu People's Hospital·N/A·NCT07461545·40 enrolled
Compare the Efficacy and Safety of Dabigatran and Enoxaparin in Patients With Portal Vein Thrombosis With Cirrhosis
Not yet recruiting·IInstitute of Liver and Biliary Sciences, India·Phase 2/3·NCT06818279·120 enrolled
Phase Ib/II Trial of Combining Pembrolizumab and Lenvatinib With SBRT for HCC Patients With Portal Vein Thrombosis.
Not yet recruiting·NNational Taiwan University Hospital·Phase 1/2·NCT05286320·27 enrolled
Percutaneous Mesenteric Vein Access for Interventional Management of Recurrent Variceal Bleeding in Occlusive Portal Vein Thrombosis: An Ambispective Cohort Study
Not yet recruiting·AAir Force Military Medical University, China·Preclinical·NCT07666256·15 enrolled
Efficacy and Safety of Anticoagulant Therapy in Portal Vein Thrombosis
Completed·QQilu Hospital of Shandong University·Phase 4·NCT04173429·64 enrolled
Apixaban, Warfarin and Aspirin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy（ESAWAAPT）
Completed·NNorthern Jiangsu People's Hospital·Phase 4·NCT04645550·120 enrolled
Placebo-controlled Study of NPB-06 in Patients With Portal Vein Thrombosis
Completed·NNihon Pharmaceutical Co., Ltd·Phase 3·NCT02250391·72 enrolled
Warfarin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy and Azygoportal Disconnection
Completed·YYangzhou University·Phase 4·NCT02247414·124 enrolled
Effect of Portal Vein Thrombosis on the Prognosis of Liver Cirrhosis
Completed·GGeneral Hospital of Shenyang Military Region·N/A·NCT02335580·475 enrolled
Xarelto Versus no Treatment for the Prevention of Recurrent Thrombosis in Patients With Chronic Portal Vein Thrombosis.
Completed·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT02555111·112 enrolled
Efficacy and Safety of Rivaroxaban in Acute Non-neoplastic Portal Vein Thrombosis in HCV
Completed·ZZagazig University·N/A·NCT03201367·40 enrolled
Apixaban Prevents Portal Vein Thrombosis After Laparoscopic Splenectomy and Azygoportal Disconnection
Completed·NNorthern Jiangsu People's Hospital·N/A·NCT05304455·40 enrolled
Efficacy and Safety of Acenocoumarol for Treatment of Nontumor Portal Vein Thrombosis in Cirrhosis of Liver
Withdrawn·IInstitute of Liver and Biliary Sciences, India·N/A·NCT01631877
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)